|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Daratumumab is a human IgG1κ monoclonal antibody targeting CD38 and is used to treat multiple myeloma.
|
31693245 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab.
|
31679012 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The model is validated with clinical data from the anti-FcRn antibody M281 and is used to conduct a scenario test to quantify the interaction among M-protein, the characteristic paraprotein of multiple myeloma (MM), and the anti-CD38 antibody daratumumab indicated for MM treatment.
|
31449666 |
2020 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38-Driven Mitochondrial Trafficking Promotes Bioenergetic Plasticity in Multiple Myeloma.
|
30622116 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantitative surface CD38 expression by multiple myeloma (MM) cells was the basic criterion used for therapeutic application of anti-CD38 monoclonal antibodies (mAbs).
|
31783629 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic monoclonal antibodies targeting SLAMF7 and CD38 are the first classes of targeted immunotherapies approved for multiple myeloma, a cancer of plasma cells.
|
31427259 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Median interval between MM diagnosis and refractoriness to CD38 MoAB (T<sub>0</sub>) was 50.1 months.
|
30858549 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, we uncovered an association between levels of CD38 expression and different MoA: (i) Isatuximab was unable to induce direct apoptosis on MM cells with CD38 levels closer to those in patients with MM, (ii) isatuximab sensitized CD38<sup>hi</sup> MM cells to bortezomib plus dexamethasone in the presence of stroma, (iii) antibody-dependent cellular cytotoxicity (ADCC) was triggered by CD38<sup>lo</sup> and CD38<sup>hi</sup> tumor plasma cells (PC), (iv) antibody-dependent cellular phagocytosis (ADCP) was triggered only by CD38<sup>hi</sup> MM cells, whereas (v) complement-dependent cytotoxicity could be triggered in less than half of the patient samples (those with elevated levels of CD38).
|
30692097 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM).
|
29741423 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combination regimens for patients with multiple myeloma (MM).
|
31270103 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab is a CD38 monoclonal antibody approved for treating relapsed/refractory and newly diagnosed multiple myeloma.
|
30795996 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic results in multiple myeloma indicate that the anti-CD38 antibodies may have relevant immunotherapeutic properties.<i>See related article by Moreno et al., p. 3176</i>.
|
30846477 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies against surface antigens on MM cells, such as anti-SLAMF7 and anti-CD38 antibodies, represent an attractive therapeutic modality for the eradication of multiple myeloma (MM) cells.
|
31115879 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM.
|
31779273 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using Cy5.5 labeling of the NP, we found that the decoration of anti-CD38 on these NP significantly increased the cellular uptake by two MM cell lines (<i>p</i> < 0.001).
|
30791634 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab (DARA) is a human IgG1κ monoclonal antibody directed against CD38, approved for the treatment of multiple myeloma.
|
30620407 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Novel anti-CD38 MAs are now approved or undergoing clinical trials to evaluate their activity in patients with multiple myeloma.
|
29369430 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy of anti-CD38 mAbs depends from the presence of CD38 on the surface of MM and immune-microenvironment cells.
|
31847204 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma.
|
30951198 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 and SLAMF7 are the main surface molecules leading to the development of monoclonal antibodies (mAbs) recently approved for the treatment of relapsing MM patients.
|
31125526 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38-positivelymphoma Daudi cell line and MM cell lines KMS-28BM and KMS-28PE were treated <i>in vitro</i> with <sup>225</sup>Ac-daratumumab.
|
31413916 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple myeloma.
|
31118070 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 is an important therapeutic target in myeloma, therefore, regulation of myeloma metabolism may play a role in the activity of this therapeutic approach.
|
31043428 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed MSI on bone marrow biopsies from patients with multiple myeloma and stained different antibodies (CD38, CD138, MUM1, kappa- and lambda).
|
30035857 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel agents such as immunomodulatory drugs, proteasome inhibitors, and immunotherapy with monoclonal antibodies targeting CD38 have been adopted from the multiple myeloma spheres with encouraging results.
|
30033840 |
2019 |